4.8 Editorial Material

New avenues for NASH therapy by targeting ACC

期刊

CELL METABOLISM
卷 34, 期 2, 页码 191-193

出版社

CELL PRESS
DOI: 10.1016/j.cmet.2022.01.001

关键词

-

向作者/读者索取更多资源

Two recent studies have found new strategies for ACC targeting in NASH therapy, successfully resolving the unwanted side effects of ACC inhibitors and bringing new hope to NASH treatment.
Acetyl-CoA carboxylase (ACC) is one of the more promising therapeutic targets for non-alcoholic steatohepatitis (NASH), but current ACC inhibitors already tested in clinical trials also exert the unwanted adverse side effect of hypertriglyceridemia. In two recent studies by Calle et al. in Nature Medicine and Zhang et al. in Science Translational Medicine, new strategies for ACC targeting were explored for NASH therapy that successfully resolved the adverse effect of hyperlipidemia while maintaining potent anti-NASH efficacy. These findings bring encouraging new momentum to the clinical application of ACC inhibition for NASH therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据